Skip to main content
Equibles
BBNX logo

BBNX · Beta Bionics, Inc. · Metrics

Track BBNX — free

Use BBNX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BBNX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$17.75 -3.64 (-17.02%) Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$962.33M
Shares
54.37M
Volume · Oct 28 2.46M Avg daily vol (3M) 1.31M

BBNX metrics

82 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$21.39
Market cap
$962.33M

Price action

20 metrics
Price change (1W)
+20.6%
Price change (30D)
+4.2%
Price change (3M)
+35.4%
Price change (6M)
+112.2%
Price change (YTD)
-29.8%
Price change (1Y)
-9.9%
Trailing year
Price change (5Y)
—
52-week high
$31.99
52-week low
$8.86
Change from 52-week high
-33.1%
Change from 52-week low
+141.4%
Annualized volatility
81.8%
Annualized volatility (3M)
79.0%
Beta
1.3
RSI (14D)
65.2
Price vs SMA 50
+11.2%
Price vs SMA 200
+44.4%
Avg volume (3M)
1.31M
Relative volume
1.1
Average dollar volume
$24.14M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
54.37M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
5.7×
reciprocal yield 17.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
7.6×
reciprocal yield 13.2%
P / book
2.4
reciprocal yield 41.7%
FCF yield
-6.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-8.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
5.2×
reciprocal yield 19.2%
EV / revenue historical average (5Y)
5.2×
reciprocal yield 19.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-27

Profitability

9 metrics
Gross margin
58.6%
Operating margin
-72.7%
Trailing 12 months
Net margin
-65.3%
Gross profit (TTM)
$74.61M
Operating profit (TTM)
−$92.58M
Net income (TTM)
−$83.12M
Trailing 12 months
Diluted EPS (TTM)
$-1.70
FCF margin
-51.8%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.83
Gross profit per diluted share (TTM)
$1.66
Operating profit per diluted share (TTM)
$-2.06
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.85
Operating cash flow per diluted share (TTM)
$-1.32
Free cash flow per diluted share (TTM)
$-1.47
Capital expenditures per diluted share (TTM)
$0.15
R&D per diluted share (TTM)
$0.95
Stock compensation per diluted share (TTM)
$0.52
Book value per share
$7.38

Growth

11 metrics
Revenue growth YoY
+30.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$127.27M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+6.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-20.7%
Return on assets
-18.7%
Debt / equity
0.0
Current ratio
8.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$65.96M
Quick ratio
8.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$240.20M
Latest balance sheet
Cash & equivalents
$81.55M
Total assets
$443.76M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$59.37M
Capital expenditures (TTM)
$6.59M
R&D (TTM)
$42.70M
SG&A (TTM)
—
Stock compensation (TTM)
$23.44M
R&D / revenue
33.6%
Stock compensation / revenue
18.4%

Ownership (13F)

9 metrics
13F filers
136
13F filer change QoQ
+5
Institutional ownership
88.5%
Conviction holders (share of 13F filers)
3.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-6.4%
Holder tenure
5.1
Price vs estimated holder cost
-8.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.1%

Short interest

3 metrics
Short interest
12.7%
Latest settlement · 7.4 days to cover
Days to cover
7.4d
Short-squeeze score
94 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$2.37M
Insider-sentiment score
19 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1674632 CUSIP 08659B102 13F (30d) 22 filings 22 filers Visit website Investor relations